According to the deep-dive market assessment study by Growth+ Reports, the global invasive aspergillosis therapeutics market was pegged at ~US$ 1,012.5 million in 2021. The market is expected to witness a CAGR of ~3.90 % from 2020 to 2030.
Rising trends of organ transplantation in chronic diseases such as cancer, renal failure is one of the major factor supporting the market potential. Patients undergone organ transplantation are regulary advised to take immunosuppressant drugs, which eventually makes them immunocompromised and become more prone to invasive aspergillosis. Moreover, rising rates of invasive aspergillosis mostly in patients suffering lung diseases such as asthma, and COPD is anticipated to increase the market in the forecast period. This rising rate are getting the focus of manufacturers and researchers in introducing many novel drugs and treatment methods.
Receipents of organ transplant are advised by healthcare proffessionals to take anti-rejection medictaions such as adalimumab, infliximab, and cyclosporin. Patients with haematological malignancies, those who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), and liver transplanatation are at the greatest risk of developing invasive aspergillosis. According to a estimate of NCBI in 2021 patients who have had liver transplants are susceptible to invasive aspergillus infections. In patients with liver transplants, the prevalence of invasive Aspergillus infection ranges from 1% to 9%. However, these patients have a death rate that is more than 90%. Aspergillus infections are thought to be the cause of 16.9% of all liver transplant recipient deaths. Similarly, It has been observed that Aspergillus infections among recipients of hematopoietic stem cell transplants happen later in the posttransplantation period, a greater percentage of these infections are caused by Aspergillus species other than aspergillus fumigatus, and the risk factors for aspergillosis appear to be varing.
This increase in prevalence rates is driving attention of many market players to increase research and development on disease and introduce new and innovative treatment methods and drugs in the market. For instance, intravenous antifungal therapy is necessary for treatment of invasive aspergillosis. Typically, the first-line treatment is voriconazole, occasionally in conjunction with additional medications like capoten. Isavuconazole, a different triazole antifungal medication, is also recommended for invasive aspergillosis. In cases where a treatment doesn't work, amphotericin may be administered.
Geographically, the global invasive aspergillosis therapeutics market is segmented into North America, Europe, Asia Pacific, and Rest of the world. North America region has dominated the market with 3.7% of CAGR. Increasing prevalence of invasive aspergillosis in the region is primary factor rising the market potential in this region. For instance, according to NCBI report of 2022 approximately 666235 fungal infections were identified in the 35.5 million inpatient visits recorded in the US in 2018, with an estimated associated cost of $6.7 billion. Infections with Aspergillus, Pneumocystis, and Candida accounted for 76.3% of identified fungal infections and 81.1% of related expenses. The European region is characterized by increasing cases of invasive aspergillosis mostly in ICU patients. Some critically ill patients with chronic diseases such as kidney disease and diabetes are highly prone to get infected by invasive aspergillosis. Thus, increasing prevalence of these chronic diseases are anticipated to highly impact the global invasive aspergillosis therapeutics market. Asia pacific region is anticipated to increase with high CAGR in the forecast period. Countries such as china, despite better awareness a consistent rise in the number of aspergillosis cases for decades is reported. an increase of vulnerable people and subspecies, and improvements in antemortem diagnosis is also noted in the region.
Some of the prominent companies operating in the global Invasive aspergillosis therapeutics market are F2G Ltd., SCYNEXIS, Inc., Pulmocide Ltd, TFF Pharmaceutical, Inc., Biosergen AB, Basilea Pharmaceutical International Ltd., Mylan Pharmaceuticals, Inc., Novartis AG, GlaxoSmithKline plc, Johnson & Johnson Services Inc.
This report entails a thorough quantitative analysis of the trends from 2022 to 2030 in the invasive aspergillosis therapeutics market. The global invasive aspergillosis therapeutics market has been analyzed from three perspectives: by drugs class, by route of administration, and by region. The drug class segment is further divided into azoles and antibiotics,. The route of administration segment is further bifuracted into oral and parentral.